- TLDR Biotech
- Archive
- Page -69
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | February 12 - 16, 2026
🧬 Vertex Pharmaceuticals and CRISPR Therapeutics project $500M combined revenue for Casgevy gene therapy by 2026, Eli Lilly stockpiles $1.5B orforglipron inventory ahead of FDA approval while Novo expands Wegovy pill internationally, Nektar Therapeutics raises $460M public offering, clinical-stage immunotherapy medicine development, Eli Lilly's Retevmo (selpercatinib) shows Ph3 success in early-stage RET fusion-positive non-small cell lung cancer, Zeon Corporation invests in Chemify to accelerate digital chemistry innovation and develop new materials, CSL Seqirus receives Australian approval for neffy (adrenaline) nasal spray treating anaphylaxis in adults and children
Biotech & Pharma Updates | February 11 - 12, 2023
🧬 Novo Nordisk plans Ireland facility expansion to produce Wegovy pill for overseas markets beyond US, CARsgen Therapeutics signs agreements for RMB370M CAR-T manufacturing base expansion in Shanghai's Jinshan District, Evommune announces $125M private placement - advancing clinical programs for inflammatory diseases, Astellas settles Myrbetriq patent litigation with Lupin and Zydus for $210 million combined upfront payments, Nxera Pharma + Centessa Pharmaceuticals milestone triggers $1.8M payment for orexin receptor agonist ORX489
Biotech & Pharma Updates | February 10 - 11, 2026
🧬 Madrigal Pharmaceuticals and Suzhou Ribo Life Science partner on MASH siRNA programs for $60M upfront + $4.4B biobucks, GSK and Teva quietly settle decade-long Coreg skinny label patent dispute over heart medication, Fujifilm Biotechnologies announces £400M ($545.3M) UK biomanufacturing expansion adding 19,000 liters single-use capacity for medicines and vaccines, Gubra launches Gubra Ventures with Zoë Johnson leading new independent biotech company creation unit, Nektar Therapeutics raises $400M public offering for clinical development and manufacturing costs, FDA approves Merck & Co.'s Keytruda (pembrolizumab) for PD-L1 positive platinum-resistant ovarian carcinoma second-line treatment, Takeda consolidates Boston operations by subleasing 630K square feet while opening new Cambridge R&D facility
Biotech & Pharma Updates | February 9 - 10, 2026
🧬 Moderna, Mexico sign five-year manufacturing pact for respiratory vaccine supply and technology transfer, Kainova Therapeutics raises $32M CAD ($23.6M) Series B - accelerating immuno-oncology and inflammation therapies, Kailera Therapeutics and Hengrui advance ribupatide for obesity to Ph3 following positive Ph2 results in China, Insilico Medicine + China Medical System partner on AI-driven CNS, autoimmune drug development for up to $9M per programme, PharmaEssentia to build $46M manufacturing plant in Puerto Rico for rare blood disease treatment Besremi
Biotech & Pharma Updates | February 8 - 9, 2026
🧬 Eli Lilly to acquire Orna Therapeutics for $2.4B for their in vivo CAR T tech - targeting autoimmunity, QuantX Biosciences raises $85M Series B for computational drug discovery platform, Aerska raises $39M Series A - developing brain shuttle technology for RNA medicines, Takeda + Iambic partner on AI drug discovery for oncology and inflammatory diseases - $1.7B+ milestones, Bristol Myers Squibb + Evinova partner on AI clinical development platform to improve efficiency and cut costs, Basilea Pharmaceutica receives $5M milestone payment from Pfizer for strong Cresemba sales in Asia Pacific
Biotech & Pharma Updates | February 5 - 8, 2026
🧬 Agomab Therapeutics + SpyGlass Pharma collectively raise $350M IPOs, inflammatory/ophthalmic treatments, Eli Lilly+ Innovent Biologics partner on oncology immunology development - $350M upfront + $8.5B milestones, GSK's Nucala (mepolizumab) wins European Commission approval for chronic obstructive pulmonary disease following Ph3 trial, Genentech's fenebrutinib (fenebrutinib) shows superiority over Ocrevus in Ph3 trial for primary progressive multiple sclerosis
Biotech & Pharma Updates | February 4 - 5, 2026
🧬 Veradermics raises $256M IPO developing oral version of Rogaine molecule, Angitia Biopharmaceuticals raises $130M Series D for bone disease bispecific antibodies development, Ginkgo Bioworks + OpenAI collaborate on autonomous laboratory achieving 40% cost reduction in cell-free protein synthesis using GPT-5, Bayer's asundexian (factor XIa inhibitor) shows 26% stroke recurrence reduction in Ph3 secondary stroke prevention trial, TrumpRx government pharmaceutical platform launches with discounted drugs from big pharma names
Biotech & Pharma Updates | February 3 - 4, 2026
🧬 Novartis CEO projects 2026 growth despite massive $4B patent cliff-caused revenue hole, Nanologica acquires Ardena's Syntagon API facility for $961K - adding 45 employees in Sweden expansion, Third Arc Bio raises $52M Series A extension for oncology/immunology antibodies, Eli Lilly's Zepbound (tirzepatide) plus Taltz combo meets Ph3b endpoints in psoriatic arthritis, Evogene + Shanghai Lishan Biopharmaceuticals license BMC128 microbiome therapeutic for renal and lung cancer, OXB, Bristol Myers Squibb expand partnership for commercial lentiviral vector manufacturing for CAR-T therapies, President Trump signs spending bill reauthorizing rare pediatric disease vouchers - ending uncertainty for rare disease developers
Biotech & Pharma Updates | February 2 - 3, 2026
🧬 Merck & Co. projects $70B+ annual revenue opportunities by mid-2030s - preparing for post-Keytruda future with expanded pipeline, AccurEdit Therapeutics raises $75M Series A to advance CRISPR gene editing pipeline, FDA announces flexible regulatory approach to shepherd CAR-T therapies for autoimmune diseases development, Insilico Medicine receives $5M milestone from Menarini Group for MEN2501 first-in-human dosing achievement, NIH Director Bhattacharya acknowledges no vaccine-autism link amid Senate hearing on agency modernization efforts, Veradermics prices upsized $256M IPO for dermatological and aesthetic therapeutics development, Pfizer's PF-08653944 demonstrates 12.3% weight loss in Ph2 trial for obesity with monthly GLP-1 receptor agonist dosing
Biotech & Pharma Updates | February 1 - 2, 2026
🧬 Novo Nordisk's CagriSema (semaglutide/cagrilintide) tops semaglutide in Ph3 type 2 diabetes trial targeting GLP-1/amylin pathways, Sanofi's venglustat (glucosylceramide synthase inhibitor) hits Ph3 goal in Gaucher disease but misses in Fabry disease, Vaxcyte raises $632.5M public offering - clinical-stage vaccine innovation company, Newsoara + vTv Therapeutics expand partnership for global HPP737 inflammation drug rights with $135M total deal value, Roche + SanegeneBio partner on RNAi programme - $200M upfront + $1.5B milestones
Biotech & Pharma Updates | January 29 - February 1, 2026
🧬 Eli Lilly picks Pennsylvania for fourth US manufacturing site in $27B domestic expansion push, AstraZeneca + CSPC Pharmaceutical partner on obesity drugs - $1.2B upfront + $18.5B biobucks, CDMO Vetter Pharma invests €480M ($574.4M) for new German production facility - targeting 2031 launch with 2,000 jobs, Lexicon Pharmaceuticals announces $94.6M public offering for drug candidate R&D, Sanofi's Rezurock (belumosudil) receives CHMP approval recommendation for chronic graft-versus-host disease treatment
Biotech & Pharma Updates | January 28 - 29, 2026
🧬 AstraZeneca pledges $15B investment in China operations through 2030 for cell therapies and radioconjugates development, Roche wants to be in the “top three” in the obesity market with personalized weight-loss pipeline against Novo Nordisk & Eli Lilly, Agomab Therapeutics aims for $212M IPO to support immunology trials for Crohn's disease candidates, Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development platform, Ascletis reports positive Ph3 safety results for denifanstat (ASC40) FASN inhibitor targeting acne vulgaris, Repertoire Immune Medicines + Eli Lilly collaborate on autoimmune tolerizing therapies with $85M upfront + $1.84B biobucks deal